PT Itama Ranoraya TbkISX:IRRA +2.25%81 EBITDA Margin % is 11.46% as of Mar. 2026, which is 3% below its 10-year median of 11.78. GuruFocus rates ISX:IRRA with a GF Score™ of 81/100 and a GF Value™ of Rp534.14 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 119 Medical Distribution companies, PT Itama Ranoraya Tbk ranks better than 79.83% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PT Itama Ranoraya Tbk EBITDA Margin % Related Terms
PT Itama Ranoraya Tbk EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PT Itama Ranoraya Tbk's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:IRRA vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, PT Itama Ranoraya Tbk's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Itama Ranoraya Tbk EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Itama Ranoraya Tbk's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PT Itama Ranoraya Tbk's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Itama Ranoraya Tbk (ISX:IRRA) has a EBITDA Margin % of 11.46% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Itama Ranoraya Tbk and its competitors. This is near median its historical median of 11.78. Over the past decade, PT Itama Ranoraya Tbk's EBITDA Margin % has ranged from 4.49 to 16.84. According to the industry distribution chart, PT Itama Ranoraya Tbk ranks #24 out of 119 companies in the Medical Distribution industry, placing it in the top 20.2%.
Is PT Itama Ranoraya Tbk's EBITDA Margin % too high?
PT Itama Ranoraya Tbk's current EBITDA Margin % of 11.46% is near median its 10-year median of 11.78. Over the past 10 years, this metric has ranged from a low of 4.49 to a high of 16.84. The Medical Distribution industry median EBITDA Margin % is 4.31. PT Itama Ranoraya Tbk's value of 11.46% is 165.9% above this industry median. Based on the distribution chart, PT Itama Ranoraya Tbk ranks #24 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, PT Itama Ranoraya Tbk has a GF Score™ of 81/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PT Itama Ranoraya Tbk's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Itama Ranoraya Tbk ranks #24 out of 119 companies for EBITDA Margin %. This places PT Itama Ranoraya Tbk in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 4.31. PT Itama Ranoraya Tbk's value of 11.46% is 165.9% above this benchmark. Historically, PT Itama Ranoraya Tbk's own EBITDA Margin % has ranged from 4.49 to 16.84 over the past decade. While the company's 10-year median is 11.78 vs. the industry median of 4.31, PT Itama Ranoraya Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Itama Ranoraya Tbk's current EBITDA Margin % of 11.46% is 165.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Itama Ranoraya Tbk and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Itama Ranoraya Tbk's current EBITDA Margin % is 11.46%, which is near median its own 10-year median of 11.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Itama Ranoraya Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Itama Ranoraya Tbk (ISX:IRRA) is currently considered Possible Value Trap. The stock's GF Value™ is Rp534.14, compared to a current price of Rp364.00 — trading 31.9% below its estimated fair value. The current EBITDA Margin % is 11.46%, which is near median its 10-year median of 11.78 and 165.9% above the Medical Distribution industry median of 4.31. PT Itama Ranoraya Tbk's overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PT Itama Ranoraya Tbk (ISX:IRRA), the current EBITDA Margin % is 11.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Itama Ranoraya Tbk (ISX:IRRA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Itama Ranoraya Tbk stock appears to be undervalued.
The current stock price of Rp364.00 is trading 31.9% below its estimated GF Value™ of Rp534.14.
GuruFocus considers PT Itama Ranoraya Tbk to be Possible Value Trap.
Key valuation signals for ISX:IRRA:
EBITDA Margin %: 11.46% (near median its 10-year median of 11.78)
GF Value™: Rp534.14 vs. price of Rp364.00 (31.9% below fair value)
Industry Position: 165.9% above the Medical Distribution median (#24 of 119)
No single metric tells the full story. See the ISX:IRRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Itama Ranoraya Tbk focuses on the trade and distribution of medical devices. The company distributes medical devices such as Oneject auto disable syringe, Abbott diagnostics, TerumoBCT, Ortho Clinical diagnostics and others. It business segment includes Vitro Diagnostic Products, Non-Electromedical Sterile Medical Devices, Electromedical Sterile Medical Devices and Other Segments. The key revenue generating segments of the company are In Vitro Diagnostic product.
81GF Score
Get the complete analysis for ISX:IRRA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:IRRA has been successfully added to your 
